Pancreatic enzyme replacement therapy (PERT) has significantly transformed the management of digestive disorders such as exocrine pancreatic insufficiency (EPI) and cystic fibrosis. This article explores the differences between two commonly prescribed PERT medications: Pancreaze and Creon. Gain insight to make informed choices, empowering both patients and healthcare professionals in selecting the most suitable treatment for optimal well-being!
Active Ingredients
Both Pancreaze and Creon consist of a blend of lipases, proteases, and amylases sourced from pig pancreas. However, the exact composition and proportions of these enzymes may vary between the two medications.
The primary ingredient in Pancreaze is pancrelipase, which is a mixture of digestive enzymes including lipases, proteases, and amylases derived from pig pancreas.
Similarly, Creon’s active ingredients are also derived from pig pancreas and include lipases, proteases, and amylases. The specific composition and proportions of these enzymes can vary based on the strength of the prescribed Creon medication.
Enzyme Strengths
Another critical factor to consider is the enzyme strength available in each medication. Pancreaze is available in various strengths to meet individual patient needs, with dosages ranging from 5000 to 42000 USP lipase units per capsule. Creon also offers a range of strengths, from 3000 to 36000 USP lipase units per capsule. The appropriate strength is determined by the severity of the patient’s condition and their response to treatment.
Administration
Pancreaze and Creon offer flexible administration options, whether swallowed whole or sprinkled on soft acidic foods like applesauce, making it easier for patients who have difficulty swallowing. It is crucial to follow the specific administration instructions provided by the prescribing healthcare professional.
FDA Approval
Both Pancreaze and Creon have gone through separate clinical trials for FDA approval. Pancreaze was approved by the FDA in 2010, while Creon received its approval a year earlier in 2009. Both medications have proven efficacy and safety in treating EPI and other related conditions.
Manufacturer
Pancreaze is produced by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, a well-known name in the healthcare industry. Creon is manufactured by AbbVie, another reputable pharmaceutical company known for developing innovative therapies.
Availability and Cost
The prices of both Pancreaze and Creon can vary based on pharmacy location, insurance coverage, and available discounts or patient assistance programs. Here’s a general overview:
The cost of Pancreaze varies, with the price for 2600 Pancreaze units (100 capsules) typically ranging from approximately $82 to $90 at different pharmacies across the United States.
Creon tends to be more expensive. On average, Creon (ranging from 6000 units to 30,000 units) costs about $218 for a supply of 100 capsules. Online Canadian Pharmacies such as Pro Health Supporter offer Creon in a price range of $84.37 – $144.41 for 100 capsules.
It is important to consult with a healthcare professional and check with your specific insurance provider or pharmacy for the most accurate and up-to-date pricing information.
Both Pancreaze and Creon are prescription medications, typically available at pharmacies in the United States with a valid prescription from a healthcare provider.